# Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

> **NCT06239194** · PHASE1,PHASE2 · RECRUITING · sponsor: **ModeX Therapeutics, An OPKO Health Company** · enrollment: 285 (estimated)

## Conditions studied

- Biliary Tract Cancer
- Breast Cancer
- Cervical Cancer
- Colon Cancer
- Endometrial Cancer
- Esophageal Cancer
- Gastric Cancer
- GastroEsophageal Cancer
- Head and Neck Cancer
- Hepatocellular Cancer
- Non-small Cell Lung Cancer
- Pancreatic Cancer
- Prostate Cancer
- Rectal Cancer
- Renal Cancer
- Thyroid Cancer

## Interventions

- **DRUG:** MDX2001

## Key facts

- **NCT ID:** NCT06239194
- **Lead sponsor:** ModeX Therapeutics, An OPKO Health Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-12
- **Primary completion:** 2028-08
- **Final completion:** 2029-02
- **Target enrollment:** 285 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06239194

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06239194, "Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06239194. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*